Home
About Novartis Oncology

About Novartis Oncology

At Novartis Oncology, our employees worldwide share a common mission: discover and develop innovative medicines to fight cancer. Headquartered in Florham Park, New Jersey, we are passionate about providing a broad range of new remedies and practical solutions that change the way patients live with cancer.

With more than 4,500 employees operating in over 50 countries, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to improving and extending the lives of patients around the world.

We have a proven track record of providing new and improved cancer treatments and are continually discovering and developing new therapies that change lives. We are currently concentrating efforts on research platforms spanning discoveries in signal transduction inhibition, cytotoxic agents, antiangiogenesis, cell cyle/apoptosis, iron chelation, metastases and hormone therapy.

Learn more at Novartisoncology.com.

Find out more about our other breakthrough products by choosing a link below.

AFINITOR^®
Afinitor (everolimus) tablets has been approved for the treatment of patients with advanced renal cell carcinoma, whose disease has progressed on or after treatment with VEGF-targeted therapy.

In cancer cells, Afinitor continuously targets mTOR, a protein that acts as a central regulator of tumor cell division, cell metabolism and blood vessel growth.

This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.

For more information and product details, please visit the Global Afinitor brand website: Afinitor.com.
(For Non US Health Care Professionals Only)

Femara^®
Femara is a prescription medication approved as an oral, once-daily tablet to treat breast cancer in postmenopausal women in the adjuvant, extended adjuvant and metastatic setting by decreasing the levels of estrogen. Femara falls into the class of breast cancer medications known as aromatase inhibitors.

The female hormone estrogen promotes the growth of some breast cancers, this type of breast cancer is called estrogen or hormone-dependent. Femara suppresses estrogen levels throughout the body, thereby helping to reduce the growth and spread of breast cancer. Because women with estrogen-dependent breast cancer have a high probability of experiencing a recurrence after initial treatment, medications like Femara are important to help guard against breast cancer returning or spreading to other parts of the body.

Femara is the only medicine of its kind to work for postmenopausal women with hormone dependent breast cancer as initial treatment immediately after surgery (adjuvant therapy), following completion of five years of tamoxifen therapy (extended adjuvant) and for women whose breast cancer has recurred or has spread to other parts of the body.

For more information and product details, please visit the Global Femara brand website: Femarainfo.com.
(For Non US Health Care Professionals Only)

ZOMETA^®
ZOMETA is the current standard of care for the prevention of skeletal-related events in patients with advanced malignancies involving bone metastases.

For more information and product details, visit the Global ZOMETA brand website: Zometa.com.
(For Non US Health Care Professionals Only)

Sandostatin^® LAR^®
Sandostatin LAR is the most prescribed and most studied medical therapy in the treatment of acromegaly and symptoms of gastro-entero-pancreatic neuroendocrine (GEP NE) tumours. Sandostatin LAR maintains all of the clinical and pharmacological characteristics of the immediate-release dosage form of subcutaneous (SC) Sandostatin^® (octreotide acetate) Injection, with the added feature of convenient, once-monthly administration. Sandostatin LAR has a well-tolerated safety profile backed by more than a decade of clinical use.

Acromegaly
In the majority of patients, Sandostatin LAR controls growth hormone (GH) and insulin-like growth factor I (IGF-I) and reduces the size of tumours to help control symptoms of acromegaly.

GEP NE tumours
In the majority of patients, Sandostatin LAR controls gastrointestinal hormone secretion to help reduce diarrhoea and flushing and suppress 5- hydroxyindoleacetic acid (5-HIAA) in patients with GEP NE tumours and carcinoid syndrome.

For more information and product details, visit the Global Sandostatin LAR brand website: Sandostatin.com.
(For Non US Health Care Professionals Only)

EXJADE^®
EXJADE is the once-daily oral breakthrough that simplifies iron chelation.

Provides 24-hour chelation coverage with once-daily oral dosing.
Has proven efficacy across a broad range of anemia types that require blood transfusion therapy (including thalassemia, sickle cell disease, myelodysplastic syndromes, Diamond-Blackfan anemia, and various other anemias).
Has a defined, clinically manageable safety profile across all age groups, including patients as young as 2 years of age. Learn more about EXJADE tolerability and monitoring.
Has an efficacy and safety profile that makes it suitable for long-term treatment.
Flexible dosing allows physicians' to increase EXJADE dose in patients not achieving their target reduction in iron burden, and decrease dose to a maintenance level for patients who have achieved their therapeutic goal.
In clinical trials, EXJADE was preferred by almost all patients transferring from Desferal^® (deferoxamine).

For more information and product details, please visit the Global EXJADE brand website: Exjade.com.
(For Non US Health Care Professionals Only)

Tasigna^®
A next-generation tyrosine kinase inhibitor designed to meet the needs of adult patients with chronic or accelerated phase PH+ CML resistant to or intolerant to at least one prior therapy including imatinib.

Clinical development of Glivec^® (imatinib mesylate) has demonstrated that targeted inhibition of Bcr-Abl kinase activity has considerable clinical efficacy in patients with Ph+ CML. Indeed, 5-year follow-up of imatinib-treated patients in the original IRIS clinical trial shows a 95% overall survival rate. However, a small percentage of patients fail to achieve an adequate response to imatinib or lose their response over time. And while adverse events with imatinib are generally mild to moderate and can be managed, a small percentage of patients discontinue imatinib therapy due to severe side effects.

Tasigna was designed to preferentially target Bcr-Abl - the key cause and driver of Ph+ CML.

Tasigna

Binds more effectively to Bcr-Abl in vitro than Glivec
Achieves a higher intracellular concentration than Glivec in vitro
Is active against 32 out of the 33 Bcr-Abl mutations most commonly associated with resistance to Glivec in vitro
Demonstrates minimal cross-intolerance with Glivec

For more information and product details, visit the Global Tasigna brand website: Tasigna.com.
(For Non US Health Care Professionals Only)

THE GLIVEC INTERNATIONAL SITE

About Novartis Oncology